Literature DB >> 16042232

The association between cognitive impairment and physical disability in multiple sclerosis.

Sharon G Lynch1, Brett A Parmenter, Douglas R Denney.   

Abstract

BACKGROUND: The association between cognitive impairment and physical disability was examined in a larger, more representative sample of patients with multiple sclerosis (MS) than in previous studies.
METHOD: Two hundred and fifty-three patients attending an MS clinic were assessed with respect to physical disability using the Expanded Disability Status Scale and cognitive impairment using a battery of neuropsychological tests.
RESULTS: Physical disability correlated with duration of disease; cognitive impairment did not. Virtually all measures derived from the cognitive battery were significantly correlated with physical disability. Three measures of speeded information processing and one involving delayed recall of verbal material were unique predictors of disability status. The relationship between cognitive impairment and physical disability was equivalent for patients with shorter (< 3 years) versus longer (> 10 years) disease duration. Cognitive impairment correlated with the rate of disability progression as reflected by the progression index.
CONCLUSION: Cognitive impairment is more closely associated with physical disability than most previous studies indicate. This relationship appears to be stable throughout the duration of MS, although this conclusion is qualified by the cross-sectional design of the study. Further attention should be paid to cognitive impairment as a possible predictor of the rate of patients' physical decline.

Entities:  

Mesh:

Year:  2005        PMID: 16042232     DOI: 10.1191/1352458505ms1182oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  22 in total

1.  Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study.

Authors:  Francesco Patti; Maria Pia Amato; Stefano Bastianello; Luisa Caniatti; Elisabetta Di Monte; Fausto Lijoi; Benedetta Goretti; Silvia Messina; Orietta Picconi; Maria Rosalia Tola; Maria Trojano
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Improvement of neuropsychological function in cognitively impaired multiple sclerosis patients treated with natalizumab: a preliminary study.

Authors:  Keith R Edwards; William A Goodman; Carl Y Ma
Journal:  Int J MS Care       Date:  2012

3.  Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study.

Authors:  Jeffrey Wilken; Robert L Kane; Cynthia L Sullivan; Mark Gudesblatt; Sylvia Lucas; Robert Fallis; Xiaojun You; Pam Foulds
Journal:  Int J MS Care       Date:  2013

4.  Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery.

Authors:  Bilge Piri Cinar; Görkem Kösehasanoğulları; Pinar Yigit; Serkan Ozakbas
Journal:  Neurol Sci       Date:  2016-11-24       Impact factor: 3.307

5.  Evolving expectations around early management of multiple sclerosis.

Authors:  Ralf Gold; Jerry S Wolinsky; Maria Pia Amato; Giancarlo Comi
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

Review 6.  Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.

Authors:  Andrew L Smith; Jeffrey A Cohen; Le H Hua
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

7.  Depression, disability and cognitive impairment in multiple sclerosis: a cross sectional Italian study.

Authors:  Flavia Mattioli; Fabio Bellomi; Chiara Stampatori; Giovanni Parrinello; Ruggero Capra
Journal:  Neurol Sci       Date:  2011-05-19       Impact factor: 3.307

8.  The role of disability and depression in cognitive functioning within 2 years after multiple sclerosis diagnosis.

Authors:  T A M Siepman; A C J W Janssens; I de Koning; C H Polman; J B Boringa; R Q Hintzen
Journal:  J Neurol       Date:  2008-05-20       Impact factor: 4.849

9.  Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosis.

Authors:  Francesco Mori; Hajime Kusayanagi; Fabio Buttari; Barbara Centini; Fabrizia Monteleone; Carolina Gabri Nicoletti; Giorgio Bernardi; Elisabetta Verdun Di Cantogno; Maria Grazia Marciani; Diego Centonze
Journal:  Funct Neurol       Date:  2012 Jul-Sep

10.  Therapeutic testosterone administration preserves excitatory synaptic transmission in the hippocampus during autoimmune demyelinating disease.

Authors:  Marina O Ziehn; Andrea A Avedisian; Shannon M Dervin; Elizabeth A Umeda; Thomas J O'Dell; Rhonda R Voskuhl
Journal:  J Neurosci       Date:  2012-09-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.